Critical Contrast: Opko Health (OPK) and Its Rivals
Opko Health (NASDAQ: OPK) is one of 115 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Opko Health to related companies based on the strength of its dividends, analyst recommendations, institutional ownership, profitability, earnings, valuation and risk.
Insider and Institutional Ownership
22.5% of Opko Health shares are owned by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 40.2% of Opko Health shares are owned by insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Opko Health and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Opko Health Competitors||-2,882.43%||-67.86%||-8.82%|
This is a breakdown of recent ratings and recommmendations for Opko Health and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Opko Health Competitors||816||3669||6686||180||2.55|
Opko Health currently has a consensus price target of $14.81, indicating a potential upside of 113.13%. As a group, “Pharmaceuticals” companies have a potential upside of 22.29%. Given Opko Health’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Opko Health is more favorable than its rivals.
Risk and Volatility
Opko Health has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Comparatively, Opko Health’s rivals have a beta of 0.90, indicating that their average stock price is 10% less volatile than the S&P 500.
Valuation & Earnings
This table compares Opko Health and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Opko Health||$1.18 billion||-$17.02 million||-40.88|
|Opko Health Competitors||$8.17 billion||$2.69 billion||-0.32|
Opko Health’s rivals have higher revenue and earnings than Opko Health. Opko Health is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Opko Health beats its rivals on 8 of the 12 factors compared.
Opko Health Company Profile
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.